Addendum to the VRTX addendum: Today’s PR makes absolutely no mention of VX-813 and VX-985, which are purportedly the follow-on PI’s to succeed Telaprevir. Such a noteworthy omission bolsters my contention in the second paragraph of #msg-42917596 that the VX-813 and VX-985 programs are effectively dead.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.